CRISPR director sells 13,679 shares after exercise
CRISPR Therapeutics director Ali Behbahani exercised 30,000 options and sold 13,679 shares in same-day transactions, with a small indirect position remaining via a trust.
Rhea-AI Filing Summary
CRISPR Therapeutics AG (CRSP) director Ali Behbahani exercised stock options for 30,000 Common Shares at $14.00 per share on September 17, 2026, and received 30,000 Common Shares. On the same date, he sold 13,679 Common Shares at a weighted average price of $57.0901 per share in multiple transactions at prices ranging from $56.97 to $57.43 per share. The exercised options were originally granted on October 18, 2016, vesting in 36 equal monthly installments beginning October 31, 2016. Following these transactions, an entity associated with him, The Ali Behbahani Revocable Trust Dated June 26, 2015, is reported as the direct beneficial owner of 29 Common Shares, with Behbahani as trustee and disclaiming beneficial ownership of any portion in which he has no pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Behbahani Ali
Role
Director
Sold
13,679 shs ($781K)
Approx. gross sale proceeds
$781K
Approx. exercise cost
$420K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F3 | 30,000 | $0.00 | $0.00 |
| Exercise | Common Shares | 30,000 | $14.00 | $420K |
| Sale | Common Shares F1 | 13,679 | $57.0901 | $781K |
| holding | Common Shares F2 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Shares — 16,637 shares (Direct);
Common Shares — 29 shares (Indirect, See Note 2)
Footnotes (3)
- F1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.97 to $57.43 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. The Reporting Person is the trustee of The Ali Behbahani Revocable Trust Dated June 26, 2015 (the "Behbahani Trust"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, of such portion of the Common Shares of the Issuer held by the Behbahani Trust in which the Reporting Person has no pecuniary interest.
- F3. This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016.
Key Figures
Options exercised: 30,000 shares
Exercise price: $14.00 per share
Shares sold: 13,679 shares
+5 more
8 metrics
Options exercised
30,000 shares
Stock option exercise into Common Shares on September 17, 2026
Exercise price
$14.00 per share
Conversion price for 30,000 Stock Option (Right to Buy) shares
Shares sold
13,679 shares
Common Shares sold on September 17, 2026
Weighted average sale price
$57.0901 per share
Weighted average price for 13,679 Common Shares sold
Sale price range
$56.97–$57.43 per share
Range of individual sale prices within the weighted-average sale
Indirect shares held
29 shares
Common Shares held by The Ali Behbahani Revocable Trust after transactions
Option grant date
October 18, 2016
Grant date of option covering 30,000 Common Shares
Option vesting schedule
36 equal monthly installments
100% of 30,000-share option vested over 36 months beginning October 31, 2016
Key Terms
weighted average price, beneficial ownership, pecuniary interest, Section 16 of the Securities Exchange Act of 1934, +1 more
5 terms
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership within the meaning of Section 16..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"held by the Behbahani Trust in which the Reporting Person has no pecuniary interest."
Section 16 of the Securities Exchange Act of 1934 regulatory
"beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934..."
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
Stock Option (Right to Buy financial
"Stock Option (Right to Buy) with respect to 30,000 Common Shares..."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CRISPR Therapeutics (CRSP) director Ali Behbahani do in this Form 4?
He exercised stock options for 30,000 Common Shares at $14.00 on September 17, 2026 and sold 13,679 of those shares the same day at a weighted average price of $57.0901 per share.
What options did Ali Behbahani exercise in CRISPR Therapeutics (CRSP)?
He exercised a stock option for 30,000 Common Shares at $14.00 per share. The option was granted on October 18, 2016, with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016.
Were these CRSP transactions made under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not marked as being under a plan, and the footnotes do not state that these transactions were made pursuant to any Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
